H. Lundbeck A/S
HLUN-A
Peringkat dalam Saham
#3035
H. Lundbeck A/S engages in the research, development, manufacturing, and... H. Lundbeck A/S engages in the research, development, manufacturing, and commercializing pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. The company offers Abilify Maintena/ Abilify Asimtufii for schizophrenia and bipolar I disorder in adults; Brintellix/Trintellix to treat depressive disorders; Rexulti/Rxulti to treat major depressive disorder and schizophrenia; Vyepti for migraine prevention; and Cipralex/Lexapro for depression. It also provides Northera for symptomatic neurogenic orthostatic hypotension; Onfi for epilepsy; Sabril for refractory complex partial seizures and infantile spasms; Ebixa for dementia, Azilect for Parkinsonโs disease; Xenazine for chorea; Deanxit for depression; Cipramil for depression and anxiety; and Cisordinol for psychosis. In addition, the company develops Eptinezumab for migraine prevention; Eptinezumab, which is in phase 3 clinical trial for cluster headache; Lu AG09222, which is in phase 2 clinical trial for migraine prevention; Lu AG13909 that is in phase 1 clinical trial for neurohormonal dysfunctions; Brexpiprazole for post-traumatic stress disorder; Lu AF28996, which is in phase 1 clinical trial for Parkinsonโs disease; MAGLi program that is in phase 1 clinical trial for neurology; Bexicaserin, which is in phase 3 clinical trial for developmental and epileptic encephalopathies; Amlenetug that is in phase 3 clinical trial for synucleinopathies; and Lu AG22515, which is in clinical phase 1 clinical trial for neurology. Lundbeck A/S has a strategic research collaboration with Contera Pharma to develop oligonucleotide-based medicines for patients living with serious neurological conditions. The company was founded in 1915 and is headquartered in Valby, Denmark.
Harga Saham
$7.16
Terakhir disinkronkan: 2026-10-19
Kapitalisasi Pasar
$6.03B
Perubahan (1 hari)
0.22%
Perubahan (1 tahun)
29.19%
Negara
DK
Perdagangan H. Lundbeck A/S (HLUN-A)
Kategori
Healthcare
Margin Operasi untuk H. Lundbeck A/S (HLUN-A)
Margin Operasi per October 2026 TTM: 27.21%
Menurut laporan keuangan dan harga saham terbaru dari H. Lundbeck A/S, margin operasi saat ini (TTM) adalah 27.21%. Pada akhir 2024, margin operasi perusahaan adalah 14.86%.
Riwayat margin operasi untuk H. Lundbeck A/S dari 2004 hingga 2026
Margin Operasi pada akhir setiap tahun
| Tahun | Margin Operasi | Mengubah |
|---|---|---|
| 2026 (TTM) | 27.21% | 4.45% |
| 2025 | 26.05% | 75.30% |
| 2024 | 14.86% | -7.41% |
| 2023 | 16.05% | 2.69% |
| 2022 | 15.63% | 26.76% |
| 2021 | 12.33% | 9.50% |
| 2020 | 11.26% | -45.84% |
| 2019 | 20.79% | -29.91% |
| 2018 | 29.66% | 15.95% |
| 2017 | 25.58% | 74.49% |
| 2016 | 14.66% | -132.77% |
| 2015 | -44.73% | -6,144.59% |
| 2014 | 0.74% | -92.94% |
| 2013 | 10.48% | -5.84% |
| 2012 | 11.13% | -47.50% |
| 2011 | 21.20% | -6.77% |
| 2010 | 22.74% | 9.38% |
| 2009 | 20.79% | -0.24% |
| 2008 | 20.84% | -15.08% |
| 2007 | 24.54% | 26.82% |
| 2006 | 19.35% | -19.11% |
| 2005 | 23.92% | -8.84% |
| 2004 | 26.24% | 0.00% |
Margin Operasi untuk perusahaan sejenis atau pesaing
| Perusahaan | Margin Operasi | Perbedaan Margin Operasi | Negara |
|---|---|---|---|
| 62.34% | -97.71% |
US
|
|
| 0.00% | - |
SE
|
|
| 0.00% | - |
FR
|
|
| 0.00% | - |
IT
|
|
| 29.76% | -98.91% |
HK
|
Apa itu Margin Operasi perusahaan?
Margin Operasi adalah indikator utama untuk menilai profitabilitas suatu perusahaan. Margin Operasi yang lebih tinggi umumnya lebih baik karena menunjukkan bahwa perusahaan mampu menjual produk atau layanan mereka dengan harga yang jauh lebih tinggi daripada biaya produksinya. Margin Operasi dihitung dengan membagi laba perusahaan dengan pendapatannya.